Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
Astera Labs director Stefan Dyckerhoff reported a mix of stock sales and an equity grant. Entities associated with him, including a trust and a limited partnership, sold a total of 12,499 shares of Astera Labs common stock on June 3, 2026 at weighted average prices of $364.246 and $365.087 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. After these transactions, individual records show continued substantial direct and indirect holdings through these entities.
On June 4, 2026, Dyckerhoff also received an award of 837 restricted stock units that will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service. Following the grant, he directly holds 60,971 shares of common stock, with additional indirect holdings held through various trusts and partnerships in which he has a pecuniary interest.
ALAB filed a Rule 144 notice reporting a proposed sale of 10,000 shares of Common Stock to be sold through Nasdaq on 06/04/2026. The filing lists issued RSUs of 8,437 (05/15/2026) and 1,563 (02/15/2026). It also discloses prior open-market sales by Jack R. Lazar of 7,500 shares on 03/05/2026 for $898,471.75 and 2,500 shares on 03/16/2026 for $325,000.00.
ALAB affiliate Stefan Dyckerhoff reported proposed sales of Common Stock via Form 144 through broker Stifel Nicolaus & Company Inc. The filing lists three proposed transactions: 11,599 shares for $2,029,828 on 04/17/2026, 13,399 shares for $2,346,435 on 04/20/2026, and 12,499 shares for $2,500,174 on 05/07/2026. The securities are Common Stock on the NYSE.
ALAB notice under Form 144 reporting a proposed sale of 30,000 shares of Common Stock acquired 09/11/2020 (listed as a Private Acquisition from Issuer/Affiliate). The filing lists multiple prior dispositions by TATE 1997 LIVING TRUST in May 2026, including sales on 05/26/2026, 05/22/2026, 05/21/2026, 05/20/2026, and 05/14/2026.
The broker identified is Morgan Stanley Smith Barney LLC. The filing supplies share counts and dollar amounts for recent transactions but does not state the timing or method for the newly proposed sale beyond the Form 144 notice.
Astera Labs, Inc. President and COO Gajendra Sanjay reported pre-planned stock sales and estate-planning transfers involving the company’s common stock. An estate planning trust referred to as "Trust 1" sold a total of 400,000 shares on May 21, 2026 in a series of open-market transactions at weighted average prices in ranges from about $288.80 to $293.50 per share, executed under a Rule 10b5-1 trading plan adopted on December 2, 2025.
The filing also shows bona fide gifts totaling 452,378 shares, including a transfer of 226,189 shares of common stock to Trust 1 for no consideration as part of estate planning. After these transactions, Sanjay holds 1,209,668 shares directly, while Trust 1 holds 5,290,402 shares, and additional 615,000-share positions are reported for separate estate planning trusts labeled Trust 2 and Trust 3, for which beneficial ownership is disclaimed except for any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported an open-market sale of 796 shares of Common Stock on May 21, 2026, at an average price of $291.0251 per share. Following this transaction, he continues to hold 103,343 shares directly.
ALAB notice of proposed and recent sales of Common stock under Rule 144 by a related holder. The filing lists prior private acquisitions of 17,508 shares (03/21/2018) and 2,492 shares (09/11/2020) and reports four sales in May 2026: 49,665 shares (05/14/2026), 8,429 shares (05/20/2026), 20,000 shares (05/21/2026) and 30,000 shares (05/22/2026).
ALAB Form 144 submission reports a proposed sale of 30,000 common shares on 05/22/2026. The filing lists prior sales by TATE 1997 LIVING TRUST during the past three months: 20,000 shares on 05/21/2026, 8,429 shares on 05/20/2026, and 49,665 shares on 05/14/2026, with dollar amounts shown alongside each trade.
Astera Labs, Inc. director and President & COO Gajendra Sanjay reported pre-planned sales of common stock tied to his estate planning trusts. On May 19, 2026, three trusts labeled Trust 1, Trust 2, and Trust 3 sold a combined 280,000 shares of Astera Labs common stock in open-market transactions.
The sales were executed automatically under a Rule 10b5-1 trading plan adopted by Sanjay on December 2, 2025. Reported weighted average sale prices ranged from about $248.40 to $251.80 per share. Following these transactions, Trust 1 held 5,464,213 shares, Trust 2 held 615,000 shares, and Trust 3 held 615,000 shares, while Sanjay also held 1,435,857 shares directly.
ALAB reports insider stock dispositions. Philip Mazzara reported multiple common stock sales in Form 144 filings: 10,000 shares on 03/02/2026, 10,000 shares on 04/01/2026, and two sales on 05/18/2026 of 9,204 shares and 4,872 shares. The filing also lists 796 shares of restricted stock dated 11/15/2024.